The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trialParminder K. Judge, William G. Herrington, Natalie Staplin et al.|Nephrology Dialysis Transplantation|2024Cited by 66